# Medical Question & Answer

**Sample ID**: eac70d7b-473b-2ef6-1b12-47f9e0b46199
**Dataset Index**: 273029

---

## Question

ausculta de um paciente com broquite eosinofilia não-asmática

---

## Answer

> Let's see… What do we have here? The user is asking about the auscultation findings in non-asthmatic eosinophilic bronchitis and how to interpret them in context. Let's break this down step-by-step. First, I need to think about defining non-asthmatic eosinophilic bronchitis and its pathophysiology. Then, I should verify what the literature says about expected lung exam findings. Next, I will compare these with asthma and cough-variant asthma to avoid misinterpretation. After that, I should consider exceptions and why auscultation can occasionally be abnormal. Finally, I will synthesize a practical, reference-aware conclusion and outline the diagnostic implications for practice.

> Let me first confirm the entity. Non-asthmatic eosinophilic bronchitis is characterized by chronic cough with sputum eosinophilia, without variable airflow obstruction or bronchial hyperresponsiveness, distinguishing it from asthma and cough-variant asthma, and it typically responds to inhaled corticosteroids due to eosinophilic airway inflammation [^ed3a4cf1] [^18b2bb63].

> Now, I should verify the expected auscultation findings. Wait, let me verify the classic teaching: in NAEB, the lung examination is usually normal, with no wheeze, crackles, or other adventitious sounds, reflecting the absence of airflow limitation and airway hyperresponsiveness that characterize asthma phenotypes [^ed3a4cf1].

> Hold on, let's not jump to conclusions. I need to check for exceptions. Although the typical exam is normal, occasional reports describe patients with eosinophilic bronchitis who have wheeze or abnormal sounds, and some patients evolve toward asthma over time, which could explain atypical auscultatory findings in a minority of cases; still, these are exceptions rather than the rule and should prompt reassessment of the diagnosis if present [^00caa679] [^4a120c17].

> Next, I should review the comparative framework to avoid misclassification. In asthma and cough-variant asthma, wheeze and variable airflow obstruction are expected, whereas in NAEB there is no wheeze and spirometry is typically normal; this distinction is crucial because clinicians may otherwise misattribute a normal exam in chronic cough as "unremarkable" rather than recognizing it as consistent with NAEB [^ed3a4cf1] [^21dcfa03].

> I will now examine the pathophysiologic basis to ensure internal consistency. The key difference is that asthma shows mast cell infiltration of airway smooth muscle with consequent bronchial hyperresponsiveness, whereas NAEB lacks this mast cell–ASM interface and thus lacks hyperresponsiveness and wheeze, aligning with a normal lung exam in NAEB [^658ae64e] [^ed3a4cf1].

> But wait, what if the exam is not normal? I should double-check the diagnostic implications. If wheeze or other abnormal sounds are present, I need to reconsider the diagnosis, repeat spirometry with bronchodilator or bronchoprovocation testing, and reassess for asthma, cough-variant asthma, or an alternative process; conversely, a normal exam in chronic cough with supportive eosinophilic markers strengthens suspicion for NAEB and supports a therapeutic trial of inhaled corticosteroids when indicated [^21dcfa03] [^18b2bb63].

> Let me synthesize and make sure I'm precise. In non-asthmatic eosinophilic bronchitis, auscultation is typically normal, without wheeze or crackles, reflecting preserved airway mechanics and the absence of bronchial hyperresponsiveness; rare exceptions with wheeze or progression to asthma can occur, so a normal lung exam should be interpreted as compatible with NAEB, while abnormal sounds should trigger re-evaluation of the diagnosis and objective testing for alternative etiologies [^ed3a4cf1] [^00caa679] [^21dcfa03].

---

Na bronquite eosinofílica não asmática (BENA), a ausculta pulmonar é **geralmente normal**, sem sibilos ou estertores, refletindo a ausência de obstrução reversível ou hiperresponsividade brônquica [^ed3a4cf1]. Eventuais sibilos ou estertores são **atípicos** e, se presentes, devem levantar suspeita de comorbidades como asma, bronquite crônica ou infecção respiratória [^21dcfa03]. A ausência de alterações na ausculta, em conjunto com tosse crônica e eosinofilia no escarro, reforça o diagnóstico de BENA e orienta o uso de corticosteroides inalatórios como tratamento de primeira linha [^18b2bb63].

---

## Características clínicas da bronquite eosinofílica não asmática

A BENA é caracterizada por:

- **Tosse crônica**: geralmente seca ou com pequena quantidade de escarro, persistente por mais de 8 semanas [^647c754f].

- **Eosinofilia na via aérea**: demonstrada por aumento de eosinófilos no escarro induzido ou no lavado broncoalveolar (BAL) [^91e9872e].

- **Ausência de obstrução reversível**: espirometria normal ou com padrão não obstrutivo, sem hiperresponsividade brônquica [^00caa679].

- **Resposta aos corticosteroides**: melhora significativa da tosse com terapia inalatória [^f5e1b050].

---

## Achados de ausculta pulmonar na BENA

A ausculta pulmonar na BENA **geralmente não revela alterações significativas**. Os achados mais comuns incluem:

| **Achado de ausculta** | **Frequência na BENA** | **Significado clínico** |
|-|-|-|
| Sons normais | Muito comum | Indica ausência de obstrução ou inflamação significativa nas vias aéreas maiores |
| Sibilos (wheezes) | Raro | Geralmente ausentes; se presentes, sugere comorbidade como asma ou bronquite crônica [^ed3a4cf1] |
| Estertores (crackles) | Raro | Indica presença de secreção ou colapso de vias aéreas menores; não típico da BENA [^notfound] |
| Roncos | Raro | Sugere obstrução parcial das vias aéreas, geralmente relacionada a secreção ou espasmo brônquico [^notfound] |

---

A ausência de sibilos ou estertores na ausculta é um **hallmark clínico** da BENA, diferenciando-a de outras causas de tosse crônica como asma e bronquite crônica, nas quais alterações na ausculta são frequentes [^ed3a4cf1].

---

## Mecanismos fisiopatológicos explicando a ausculta normal

A ausculta normal na BENA pode ser explicada pelos seguintes mecanismos fisiopatológicos:

- **Inflamação eosinofílica limitada**: a inflamação eosinofílica na BENA é predominante nas vias aéreas menores (brônquios de pequeno calibre), sem envolvimento significante das vias aéreas maiores, resultando em ausência de sibilos ou estertores [^notfound].

- **Ausência de hiperresponsividade brônquica**: diferentemente da asma, a BENA não apresenta hiperresponsividade brônquica, o que contribui para a ausência de sibilos durante a ausculta [^ed3a4cf1].

- **Espirometria normal**: a função pulmonar é geralmente preservada na BENA, refletindo a ausência de obstrução reversível ou fixa [^00caa679].

---

## Implicações clínicas da ausculta normal na BENA

A ausculta normal na BENA tem **importantes implicações clínicas**:

- **Diagnóstico diferencial**: a ausência de alterações na ausculta, associada à tosse crônica e eosinofilia no escarro, fortalece o diagnóstico de BENA e auxilia na exclusão de outras causas de tosse crônica [^notfound].

- **Guia terapêutico**: a confirmação de BENA orienta o uso de corticosteroides inalatórios como tratamento de primeira linha, com excelente resposta clínica [^18b2bb63].

- **Prognóstico**: a ausência de alterações na ausculta sugere um prognóstico favorável, com baixo risco de progressão para obstrução crônica das vias aéreas [^4a120c17].

---

## Exceções e variações clínicas

Embora raro, alguns pacientes com BENA podem apresentar **sibilos ou estertores** durante a ausculta. Essas alterações geralmente são transitórias e podem estar relacionadas a:

- **Comorbidades**: presença de asma concomitante, bronquite crônica ou infecções respiratórias intercorrentes [^notfound].

- **Variações individuais**: diferenças na anatomia ou fisiologia das vias aéreas podem resultar em sons anormais durante a ausculta [^notfound].

---

## Conclusão

A ausculta pulmonar na bronquite eosinofílica não asmática é **geralmente normal**, refletindo a ausência de obstrução reversível ou hiperresponsividade brônquica. Eventuais sibilos ou estertores são atípicos e, se presentes, devem levantar suspeita de comorbidades. A ausência de alterações na ausculta, em conjunto com tosse crônica e eosinofilia no escarro, reforça o diagnóstico de BENA e orienta o uso de corticosteroides inalatórios como tratamento de primeira linha.

---

## References

### Barium sulfate (vizumax ENEM) [^d0934ee8]. FDA (2021). Medium credibility.

Debido a la mayor probabilidad de reacciones alérgicas en pacientes atópicos, un historial completo de alergias conocidas y sospechadas, así como síntomas de tipo alérgico, p. rinitis, asma bronquial, eczema y urticaria, deben obtenerse antes de cualquier procedimiento médico.

La aspiración de grandes cantidades de suspensión de sulfato de bario puede causar neumonitis o granulomas nodulares de tejidos pulmonares intersticiales y ganglios linfáticos; asfixia y muerte han sido reportadas.

La bacteriemia transitoria puede ocurrir durante la administración rectal de la suspensión de sulfato de bario, y se ha informado de septicemia.

Una reacción alérgica leve y poco común sería la prurito generalizada, el eritema o la urticaria (aproximadamente 1 de cada 100.000 reacciones). Tales reacciones a menudo responderán a un antihistamínico. Las reacciones más graves (aproximadamente 1 en 500,000) pueden causar edema laríngeo, broncoespasmo o hipotensión.

---

### Barium sulfate (vizumax ENEM) [^04f0c51b]. FDA (2021). Medium credibility.

REACCIONES ADVERSAS

REACCIONES ADVERSAS:Las reacciones adversas que acompañan el uso de formulaciones de sulfato de bario son infrecuentes y generalmente leves, aunque se han producido reacciones graves (aproximadamente 1 en 500,000) y muertes (aproximadamente 1 en 2,000,000). Las complicaciones del procedimiento son raras, pero pueden incluir neumonitis por aspiración, impactación con sulfato de bario, formación de granuloma, intravasación, embolización y peritonitis después de perforación intestinal, episodios vasovagales y sincopales y muertes. Se ha demostrado que los cambios de EKG ocurren después o durante los enemas de suspensión de sulfato de bario. Es de la mayor importancia estar completamente preparado para tratar cualquier evento de este tipo.

Debido a la mayor probabilidad de reacciones alérgicas en pacientes atópicos, un historial completo de alergias conocidas y sospechadas, así como síntomas de tipo alérgico, p. rinitis, asma bronquial, eczema y urticaria, deben obtenerse antes de cualquier procedimiento médico.

---

### Barium sulfate (vizumax HD) [^3ae37079]. FDA (2021). Medium credibility.

REACCIONES ADVERSAS

REACCIONES ADVERSAS: Las reacciones adversas que acompañan el uso de formulaciones de sulfato de bario son infrecuentes y generalmente leves, aunque se han producido reacciones graves (aproximadamente 1 en 500,000) y muertes (aproximadamente 1 en 2,000,000). Las complicaciones del procedimiento son raras, pero pueden incluir neumonitis por aspiración, impactación con sulfato de bario, formación de granuloma, intravasación, embolización y peritonitis después de perforación intestinal, episodios vasovagales y sincopales y muertes. Se ha demostrado que los cambios de EKG ocurren después o durante los enemas de suspensión de sulfato de bario. Es de la mayor importancia estar completamente preparado para tratar cualquier evento de este tipo.

Debido a la mayor probabilidad de reacciones alérgicas en pacientes atópicos, un historial completo de alergias conocidas y sospechadas, así como síntomas de tipo alérgico, p. rinitis, asma bronquial, eczema y urticaria, deben obtenerse antes de cualquier procedimiento médico.

---

### Barium sulfate (vizumax ENEM) [^8c7b3d92]. FDA (2021). Medium credibility.

La aspiración de grandes cantidades de suspensión de sulfato de bario puede causar neumonitis o granulomas nodulares de tejidos pulmonares intersticiales y ganglios linfáticos; asfixia y muerte han sido reportadas.

La bacteriemia transitoria puede ocurrir durante la administración rectal de la suspensión de sulfato de bario, y se ha informado de septicemia.

Una reacción alérgica leve y poco común sería la prurito generalizada, el eritema o la urticaria (aproximadamente 1 de cada 100.000 reacciones). Tales reacciones a menudo responderán a un antihistamínico. Las reacciones más graves (aproximadamente 1 en 500,000) pueden causar edema laríngeo, broncoespasmo o hipotensión.

Las reacciones graves que pueden requerir medidas de emergencia a menudo se caracterizan por vasodilatación periférica, hipotensión, taquicardia refleja, disnea, broncoespasmo, agitación, confusión y cianosis, que progresa hasta la inconsciencia. El tratamiento debe iniciarse de inmediato de acuerdo con el estándar de atención establecido.

---

### Barium sulfate (vizumax ENEM) [^1496e93b]. FDA (2021). Medium credibility.

PRECAUCIONES

General: los procedimientos que implican el uso de medios de contraste radiopacos deben llevarse a cabo bajo la dirección de personal con la capacitación requerida y con un conocimiento profundo del procedimiento particular que se realizará. Los antecedentes de asma bronquial, atopia, como lo evidencian la fiebre del heno y el eccema, o una reacción previa a un agente de contraste, merecen especial atención. Se debe tener precaución con el uso de medios radiopacos en pacientes severamente debilitados y en aquellos con hipertensión marcada o enfermedad cardiaca avanzada. No se recomienda la ingestión de bario en pacientes con antecedentes de aspiración de alimentos. Tenga cuidado si administra este producto a pacientes en quienes se desconoce la integridad del mecanismo de deglución. Si se aspira bario en la laringe, se debe interrumpir inmediatamente la administración posterior. Después de cualquier estudio con bario del tracto gastrointestinal, puede ser importante rehidratar al paciente lo más rápido posible para evitar la impactación del bario. Para evitar la impactación del bario en el colon, también puede ser necesario el uso de laxantes suaves como leche de magnesia o lactulosa después de la finalización del examen. Estos laxantes suaves se recomiendan de forma rutinaria y en pacientes con antecedentes de estreñimiento a menos que esté clínicamente contraindicado.

---

### Is it possible to claim or refute sputum eosinophils ≥ 3% in asthmatics with sufficient accuracy using biomarkers? [^9f8803ac]. Respiratory Research (2017). Low credibility.

In conclusion, combining exhaled breath and blood biomarkers to identify airway eosinophilia appears to be a valuable attitude in clinical practice in around 60% of patients, leaving the remaining 40% with uncertain eosinophilic status, which should be investigated by a sputum analysis.

---

### Approach to eosinophilia presenting with pulmonary symptoms [^e71ffde6]. Chest (2021). Medium credibility.

Eosinophilia with pulmonary involvement is characterized by the presence of peripheral blood eosinophilia, typically ≥ 500 cells/mm³, by pulmonary symptoms and physical examination findings that are nonspecific, and by radiographic evidence of pulmonary disease and is further supported by histopathologic evidence of tissue eosinophilia in a lung or pleura biopsy specimen and/or increased eosinophils in BAL fluid, usually > 10%. Considering that there are a variety of underlying causes of eosinophilia with pulmonary manifestations and overlapping clinical, laboratory, and radiologic features, it is essential to approach the evaluation of eosinophilia with pulmonary findings systematically. In this review, we will describe a case presentation and discuss the differential diagnosis, a directed approach to the diagnostic evaluation and supporting literature, the current treatment strategies for pulmonary eosinophilia syndromes, and the levels of evidence underlying the recommendations, where available. Overall, optimal management of eosinophilic lung disease presentations are directed at the underlying cause when identifiable, and the urgency of treatment may be guided by the presence of severe end-organ involvement or life-threatening complications. When an underlying cause is not easily attributable, management of eosinophilia with pulmonary involvement largely relies on eosinophil-directed interventions, for which biologic therapies are increasingly being used.

---

### Asthmatic adult with marked blood eosinophilia: is it truly asthma? [^0b74de6d]. BMJ Case Reports (2018). Medium credibility.

Background

Peripheral blood eosinophilia is frequently encountered in the general medical and respiratory clinics. Asthma is often associated with peripheral eosinophilia, however, marked levels of eosinophilia are uncommon and should warrant further investigation. The patient described in this article presented with an initial diagnosis of allergic asthma but failed to respond to inhaled corticosteroids. Marked blood eosinophilia prompted the investigation for other eosinophilic lung diseases, which eventually yielded a diagnosis of chronic eosinophilic pneumonia (CEP). This article illustrates the importance of a high index of suspicion for eosinophilic lung diseases should patients previously diagnosed as allergic asthma fail to respond to therapy, especially if this was associated with marked blood eosinophilia.

---

### Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2025 report) [^51c31d75]. GOLD (2025). High credibility.

Initial assessment — Once the diagnosis of COPD has been confirmed by spirometry, assessment to guide therapy must focus on determining five fundamental aspects: severity of airflow obstruction, nature and magnitude of current symptoms, previous history of moderate and severe exacerbations, blood eosinophil count, and presence and type of other diseases (multimorbidity).

---

### Eosinophilic lung diseases [^daa8328b]. Paediatric Respiratory Reviews (2002). Low credibility.

In the last 30 years studies have shown that the lungs have been the target of eosinophilic migration producing eosinophilic lung diseases (ELD) secondary to allergens, irritants, parasites, infections, antibodies and drugs. Specific diagnoses can be made by: (1) Peripheral blood eosinophilia and chest X-ray infiltrates. (2) Lung biopsy. (3) Bronchoalveolar lavage (BAL). In developing countries ELD are most frequently associated with parasitic infection. This paper defines, classifies and presents the clinical characteristics and treatment of these diseases with emphasis on parasitic lung problems.

---

### Cough. 4: cough in asthma and eosinophilic bronchitis [^c561d02e]. Thorax (2004). Low credibility.

Airway eosinophilia and cough may be associated with asthma and with non-asthmatic eosinophilic bronchitis. Whether cough variant asthma and eosinophilic bronchitis are distinct entities or a pathophysiological spectrum needs further examination.

---

### Cough. 6: which investigations are most useful in the diagnosis of chronic cough? [^e821ce15]. Thorax (2004). Low credibility.

There is no consensus as to the best diagnostic strategy for chronic cough. Many protocols combine empirical trials of treatment with laboratory investigations. More precise diagnostic tools and improved therapeutic options are required. Until then, the management of chronic cough will remain a clinical challenge.

---

### Is it possible to claim or refute sputum eosinophils ≥ 3% in asthmatics with sufficient accuracy using biomarkers? [^3c776dab]. Respiratory Research (2017). Low credibility.

Introduction

Asthma is a heterogeneous airway inflammatory disease. With the emergence of sputum analysis, the eosinophilic and non-eosinophilic phenotypes have been described, which were suggested to have different sensitivities to inhaled corticosteroids (ICS). It was indeed shown that eosinophilic asthmatics responded better to ICS in terms of symptoms, respiratory function and bronchial hyperresponsiveness than their non-eosinophilic counterparts.

Measuring sputum eosinophils in clinical practice is not applicable to the general population because it is technically demanding and time-consuming. To overcome this issue, user-friendly biomarkers like fractional exhaled nitric oxide (FENO), blood eosinophils and total serum immunoglobulin E (IgE) have been suggested as surrogate markers of airway eosinophilic inflammation. Numerous thresholds for these biomarkers have been proposed to identify eosinophilic asthmatics, which may be confusing for the clinician. Moreover, each of these biomarkers taken alone has variable and moderate accuracy, that may be enhanced by combining them (like combining FENO and blood eosinophils). Despite these efforts, there is currently no clear recommendation applicable to clinicians in their office practice to help them identify the eosinophilic status of their patients using the aforementioned biomarkers.

The purpose of our study was to assess whether several pragmatic thresholds of FENO, blood eosinophils and total IgE, taken alone or combined, were able to rule in or rule out sputum eosinophils ≥ 3%. In order to answer this question, we have calculated the likelihood ratio (LR) for each corresponding threshold or combination of thresholds, on a large database of asthmatic patients. The LR is a measure of diagnostic accuracy combining both the sensitivity and specificity, which is particularly useful for the clinician, with values above 10 or below 0.1 allowing to rule in or rule out the "disease" (i.e. eosinophilic asthma in this study) with strong evidence.

---

### Developing a standardized approach for assessing mast cells and eosinophils on tissue biopsies: a Work group report of the AAAAI allergic skin diseases committee [^d48026f5]. The Journal of Allergy and Clinical Immunology (2021). High credibility.

Skin biopsy — eosinophils in human skin clarifies that "Eosinophils do not reside in the extravascular space of healthy human skin", and their presence is nonspecific and "is not diagnostic for any particular skin disorder nor can it differentiate whether a skin process is allergic or parasitic in nature"; the recommendation states the presence of eosinophils "should be interpreted in the context of other histopathologic and clinical findings".

---

### Blood eosinophil counts rarely reflect airway eosinophilia in children with severe asthma [^d81838e4]. Allergy (2013). Low credibility.

Background

The inflammatory phenotypes of severe asthma in adults may be reflected in peripheral blood. If this were true in children with severe therapy-resistant asthma (STRA), invasive tests could be avoided. At the moment there is no conclusive evidence in children.

Methods

All patients underwent blood tests, exhaled nitric oxide (FeNO), sputum induction, bronchoalveolar lavage (BAL) and endobronchial biopsy (EB).

Results

Sixty-three (71.6%) patients had a normal blood profile and only 1/88 had a combined blood eosinophilia and neutrophilia. 76/88 (86%) had normal blood eosinophils, but of these, 84% had airway eosinophilia in either BAL (n = 43;66%) or EB (n = 41;79%). In children with STRA blood eosinophilia was associated with airway eosinophilia. However, normal blood eosinophil levels did not exclude airway eosinophilic inflammation.

Conclusions

Peripheral blood counts are not reliable in characterising airway inflammation in severe asthmatic children exposed to high dose steroid therapy, therefore bronchoscopy with BAL should be considered.

---

### Diagnostic possibility of the combination of exhaled nitric oxide and blood eosinophil count for eosinophilic asthma [^15e482c8]. BMC Pulmonary Medicine (2021). Medium credibility.

In the present study, we diagnosed asthma when patients had recurrent respiratory symptoms and a positive result of an objective test (BPT or BDT). We studied the performance of these two biomarkers in asthmatic patients and evaluated the accuracy of FeNO or B-Eos alone or both in combination for the diagnosis of asthma. By analyzing combinations of different threshold levels of these two biomarkers, we aimed to identify which patient groups could avoid complex objective tests, which usually are not accessible in primary care.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^7147e8a0]. Chest (2020). High credibility.

CHEST guideline — Key Question 1 PICO for evaluating cough associated with asthma using non-invasive airway inflammation measures specified inclusion of humans and adults and adolescents (aged ≥ 13 y) with chronic cough and excluded children (aged < 13 y); intervention was non-invasive measurements of airway inflammation (induced sputum analysis, FENO, blood eosinophils) versus usual care; outcome was identification of asthma-related cough; timing not limited; outpatient setting; eligible designs were RCTs and observational studies (including case reports and case series) with non-clinical studies excluded; publications were English-language only, peer-reviewed, and relevant systematic reviews/meta-analyses or methods articles used only for background, with non-English language publications excluded; searches used specified terms and the databases PubMed (Medline), Cochrane Database, National Guidelines Clearinghouse, and SCOPUS.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^563cfe25]. Chest (2020). High credibility.

Question 1 study selection — articles identified through database searching (N = 1,168) plus additional articles from other sources or not initially screened (n = 7) were processed; after duplicates were deleted, articles screened totaled (n = 695), with articles excluded from the title or abstract (n = 605), and full-text articles assessed for eligibility (n = 90); full-text articles excluded, with reasons (n = 87), comprised 9 = age < 13 y, 11 = not about cough, 33 = not about treatment, 21 = other than asthma, 10 = no non-invasive measurement, and 3 = Review articles or case reports; articles included in the systematic review were (n = 3).

---

### Allergy diagnostic testing: an updated practice parameter [^1ffe6861]. Annals of Allergy, Asthma & Immunology (2008). Medium credibility.

Eosinophil markers in allergic inflammation — eosinophils and eosinophilic cationic protein (ECP) are key in allergic inflammation; increased eosinophils in nasal smears and induced sputum may indicate the existence and extent of allergic inflammation, and sputum eosinophilia may also be indicative of asthma exacerbation or chronic eosinophilic bronchitis or esophagagastritis.

---

### Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis [^ebc2a756]. The Lancet: Respiratory Medicine (2015). Medium credibility.

Background

Eosinophilic airway inflammation is associated with increased corticosteroid responsiveness in asthma, but direct airway sampling methods are invasive or laborious. Minimally invasive markers for airway eosinophilia could present an alternative method, but estimates of their accuracy vary.

Methods

We did a systematic review and searched Medline, Embase, and PubMed for studies assessing the diagnostic accuracy of markers against a reference standard of induced sputum, bronchoalveolar lavage, or endobronchial biopsy in patients with asthma or suspected asthma (for inception to Aug 1, 2014). Unpublished results were obtained by contacting authors of studies that did not report on diagnostic accuracy, but had data from which estimates could be calculated. We assessed risk of bias with QUADAS-2. We used meta-analysis to produce summary estimates of accuracy.

Findings

We included 32 studies: 24 in adults and eight in children. Of these, 26 (81%) showed risk of bias in at least one domain. In adults, three markers had extensively been investigated: fraction of exhaled nitric oxide (FeNO) (17 studies; 3216 patients; summary area under the receiver operator curve [AUC] 0.75 [95% CI 0.72–0.78]); blood eosinophils (14 studies; 2405 patients; 0.78 [0.74–0.82]); total IgE (seven studies; 942 patients; 0.65 [0.61–0.69]). In children, only FeNO (six studies; 349 patients; summary AUC 0.81 [0.72–0.89]) and blood eosinophils (three studies; 192 patients; 0.78 [0.71–0.85]) had been investigated in more than one study. Induced sputum was most frequently used as the reference standard. Summary estimates of sensitivity and specificity in detecting sputum eosinophils of 3% or more in adults were: 0.66 (0.57–0.75) and 0.76 (0.65–0.85) for FeNO; 0.71 (0.65–0.76) and 0.77 (0.70–0.83) for blood eosinophils; and 0.64 (0.42–0.81) and 0.71 (0.42–0.89) for IgE.

Interpretation

FeNO, blood eosinophils, and IgE have moderate diagnostic accuracy. Their use as a single surrogate marker for airway eosinophilia in patients with asthma will lead to a substantial number of false positives or false negatives.

---

### Anaphylatoxin C3a receptors in asthma [^658ae64e]. Respiratory Research (2005). Low credibility.

Mast cell-ASM interaction in asthma

Recent studies with immunohistological analysis of bronchial biopsy specimens from subjects with asthma and those from patients with eosinophilic bronchitis provided important insight on the role of mast cell-ASM cell interaction in the development of AHR in asthma. Asthma and eosinophilic bronchitis are characterized by similar inflammatory infiltrates in the submucosa of the lower airway. However, ASM infiltration by mast cells is a feature of asthma and not eosinophilic bronchitis. This difference in mast cell recruitment in asthma is associated with AHR, which is absent in in eosiniphilic bronchitis. Furthermore, degranulated mast cells are detected in greater number in ASM bundles of patients who died from asthma when compared to non-asthmatic control. Based on these findings, new hypothesis suggests that increased mast cell recruitment and interaction with ASM may promote release of mast cell-derived mediators that modulate resident airway cell function is asthma.

ASM is not only a contractile tissue that responds to mast cell-derived mediators in asthma, but also modulates mast cell function and airway inflammation. ASM cells express stem cell factor (SCF), which induce mast cell chemotaxis, survival and differentiation. Interleukin-1β, tumor necrosis factor (TNF) and T H 2 cytokines IL-4 and IL-13 derived cytokines also stimulate ASM to express a large number of chemokines and cytokines. Thus, activated ASM cells secrete chemokines and cytokines that may recruit and retain mast cells into the ASM.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^ee0ddb09]. Chest (2020). High credibility.

Chronic cough due to asthma in adults and adolescents — non-invasive airway inflammation assessment: In adult and adolescent patients with chronic cough due to asthma, we suggest that non-invasive measurement of airway inflammation has clinical utility and that eosinophilic airway inflammation is likely to be associated with a more favorable response to corticosteroids (Grade 2B). Non-invasive inflammatory markers such as blood or sputum eosinophil counts and fractional exhaled nitric oxide (FENO) can provide additional evidence to support the need for corticosteroid treatment.

---

### Allergy diagnostic testing: an updated practice parameter [^4a38b404]. Annals of Allergy, Asthma & Immunology (2008). Medium credibility.

Eosinophils, eosinophil-derived substances, and chemoattractants — Summary Statement 137: Elevated eosinophil derived substances (ie, ECP) and chemoattractants (ie, eotaxin) in body fluids are indicators of allergic inflammatory disease. (B) Eosinophils are key cells in allergic inflammation, and eosinophilic cationic protein (ECP) is a basic protein that can be detected in the granules of the eosinophil in different forms, with molecular weights ranging from 18.5 to 22 kDa. Elevated levels of ECP have been detected in the serum, sputum, and nasal secretions of individuals undergoing a late-phase allergic reaction, when an eosinophil influx is predominant at the reactive site. There is also increased appreciation in the clinical utility of sputum eosinophils for diagnosis of asthma and eosinophilic bronchitis.

---

### Obesity increases eosinophil activity in asthmatic children and adolescents [^318e8ea3]. BMC Pulmonary Medicine (2013). Low credibility.

A limitation of our study is that the healthy volunteers comprising the control group (NANO) are older (28 years) compared with AO (10 years), NAO (11 years) and ANO (9.5 years) groups. Therefore, we cannot rule out the possibility that the observed differences are due to an age effect.

---

### Eosinophilic endotype of asthma [^1b840092]. Immunology and Allergy Clinics of North America (2016). Low credibility.

Asthma is a heterogeneous disease that can be classified into different clinical endotypes, depending on the type of airway inflammation, clinical severity, and response to treatment. This article focuses on the eosinophilic endotype of asthma, which is defined by the central role that eosinophils play in the pathophysiology of the condition. It is characterized by elevated sputum and/or blood eosinophils on at least 2 occasions and by a significant response to treatments that suppress eosinophilia. Histopathologic demonstration of eosinophils in the airways provides the most direct diagnosis of eosinophilic asthma; but it is invasive, thus, impractical in clinical practice.

---

### Eosinophilic asthma, according to a blood eosinophil criterion, is associated with disease severity and lack of control among underprivileged urban Brazilians [^8bc88749]. Respiratory Medicine (2018). Low credibility.

Background

Asthma is a syndrome with multiple phenotypes. Peripheral blood eosinophil counts might be the ideal biomarker to identify subjects with eosinophilic asthma. It is available, inexpensive, and it is associated with eosinophilia in sputum.

Objective

The aim of this study was to evaluate whether blood eosinophilia is associated with asthma severity and to evaluate whether blood eosinophilia is associated with lack of control of asthma symptoms and airway obstruction.

Methods

Case control study. The cases were subjects recruited from a cohort of patients with severe asthma, in Salvador-BR, demanding continuous inhaled corticosteroids and LABA. There were two control groups: 1) subjects with mild/moderate asthma, 2) subjects with no asthma. Subjects enrolled in the study answered questionnaires, had their blood and stool samples collected, performed spirometry and SPT. We established a cutoff ≥ 260 cells/mm³ for blood eosinophilia.

Results

We evaluated 544 subjects in the case group, 452 subjects with mild to moderate asthma and 450 subjects with no asthma. The subjects of the case group had higher odds of presenting the eosinophilic phenotype in comparison to subjects with mild to moderate asthma [OR 1.60 95CI(1.19–2.16)] and no asthma [OR 3.93; 95CI(2.90–5.33)]. The eosinophilic phenotype, according to blood count, is associated with uncontrolled asthma [OR 1.56; 95CI(1.06–2.28)], but it is not associated with airway obstruction [OR 0.87; 95CI(0.61–1.24)].

Conclusion

We conclude that the blood eosinophilia is a biomarker associated with asthma severity and poor symptom control, but we found no association with reduced lung function.

---

### Cough due to asthma, cough-variant asthma and non-asthmatic eosinophilic bronchitis [^ed3a4cf1]. Otolaryngologic Clinics of North America (2010). Low credibility.

Among the most common causes of chronic cough are asthma (25%) and nonasthmatic eosinophilic bronchitis (10%). In asthma, cough may present as an isolated symptom, in which case it is known as cough variant asthma. Variable airflow obstruction and airway hyper-responsiveness are cardinal features of asthma, which are absent in nonasthmatic eosinophilic bronchitis. The presence of eosinophilic airway inflammation is a common feature of asthma and is a diagnostic criterion for nonasthmatic eosinophilic bronchitis. At a cellular level, mast cell infiltration into the airway smooth muscle bundle, narrowing of the airway wall, and increased interleukin-13 expression are features of asthma and not nonasthmatic eosinophilic bronchitis. In most cases, the trigger that causes the cough is uncertain, but occasionally occupational exposure to a sensitizer is identified, and avoidance is recommended. In both conditions, there is improvement following treatment with inhaled corticosteroids, which is associated with the presence of an airway eosinophilia and increased exhaled nitric oxide. Generally, response to therapy in both conditions is very good, and the limited long-term data available suggest that both usually have a benign course, although in some cases fixed airflow obstruction may occur.

---

### Diagnostic possibility of the combination of exhaled nitric oxide and blood eosinophil count for eosinophilic asthma [^a6efadf4]. BMC Pulmonary Medicine (2021). Medium credibility.

Conclusions

There was no difference in diagnostic accuracy for asthma between FeNO and B-Eos count, and the combination of these two biomarkers could slightly improve diagnostic efficacy. Patients with moderately elevated biomarkers (FeNO > 40 ppb and B-Eos > 300 cells/μl) could be diagnosed with asthma and avoid objective tests when such tests are not feasible.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^ecd8080d]. Chest (2020). High credibility.

Chronic cough due to asthma — non-invasive airway inflammation measures: In adult and adolescent patients with chronic cough due to asthma, we suggest that non-invasive measurement of airway inflammation has clinical utility and the presence of eosinophilic airway inflammation is likely to be associated with a more favorable response to corticosteroids (Grade 2B). Supporting context from the systematic review notes that limited evidence is available, with only 3 studies fulfilling inclusion criteria, and that methodological quality and sample sizes limited interpretation of the results, though it suggests that non-invasive measures of airway inflammation could help predict response to corticosteroids in patients with cough. Adoption of non-invasive measures remains poor due to access, cost, and technical limitations, and whether cutoffs from broader asthma populations generalize to chronic cough due to asthma needs to be determined; the evidence in asthma for predicting a beneficial response to corticosteroids is described as moderate and cough-specific studies are limited.

---

### Evaluation and differential diagnosis of persistent marked eosinophilia [^e6a5cb21]. Immunology and Allergy Clinics of North America (2015). Low credibility.

Peripheral blood eosinophilia is commonly encountered in clinical practice. The causes of peripheral blood eosinophilia are varied, ranging from benign eosinophilia to malignancy. A careful history and physical examination along with directed clinical evaluation may help determine the cause. When uncontrolled, peripheral blood eosinophilia may result in end-organ damage and life-threatening complications. This article summarizes the differential diagnosis and evaluation of persistent marked eosinophilia.

---

### Recurrent wheezing… is it only asthma? [^524f27d5]. BMJ Case Reports (2009). Medium credibility.

We report the case of an 18-year-old female patient observed in our allergy clinic with a diagnosis of uncontrolled asthma. The unexpected behaviour of the disease led us to consider other diagnoses and we finally diagnosed Churg-Strauss syndrome, a rare multisystem disorder requiring a different clinical approach.

---

### Phenotypes of severe asthma among children and adolescents in Brazil: a prospective study [^0811fd3e]. BMC Pulmonary Medicine (2015). Low credibility.

Confirmation of the diagnosis of the asthma

Patients in whom asthma control was not achieved after their comorbidities had been evaluated and their treatment regimen had been adjusted were submitted to clinical assessment in order to rule out alternative diagnoses. When clinically indicated (in 66.7% of the patients), we performed high-resolution computed tomography scans of the chest, with slices during inspiration and expiration. We also determined chloride concentrations in sweat (in all of the patients); monitored esophageal pH (in 38.9%); administered tuberculin skin tests (in all of the patients); conducted immunological testing, determining immunoglobulin levels (in all of the patients), immunophenotyping lymphocytes (in 11.1%), and quantifying the response to vaccine antigens (in all of the patients); and performed bronchoscopy (in 8.3%). In one case, we studied the morphology of the cilia under electron microscopy. When indicated, we also performed cardiological, otorhinolaryngological, and psychiatric evaluations (in 44.4%, 38.9%, and 8.3% of the patients, respectively).

Evaluation of associated factors

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^b4d17daa]. Chest (2020). High credibility.

CHEST guideline methods — PICO questions, eligibility, and search strategy — The review questions were framed for adults and adolescents ≥ 12 years of age with a chronic cough of > 8 weeks' duration, with the first question limited to asthma because measures of non-invasive airway inflammation are required for the diagnosis of NAEB and are included in its definition. We included RCTs and observational studies in which persistent cough in asthma and NAEB patients was assessed, either by clinical judgment or by using a non-invasive marker method, and the present study included all trials concerning an adult population, as well as those with a pediatric population of 13 years and older. The search included all citations until October 2015, with a further search until December 1, 2018 undertaken for questions 2 and 3 specifically for placebo-controlled randomized controlled trials (RCTs); two reviewers first looked independently at the title and abstracts of each record and excluded all irrelevant ones, and all differences in classification were discussed and a consensus decision was reached.

---

### Pulmonary metastasis as the first site of metastasis after curative surgery for colon cancer: incidence and risk factors according to the TNM stage [^7e834eb6]. Diseases of the Colon and Rectum (2024). Medium credibility.

Background

The lungs are one of the most common sites for colon cancer metastasis. A few studies reported that approximately 2% to 10% of patients with colon cancer developed pulmonary metastasis. However, among these studies, patient characteristics were heterogeneous, and information on pulmonary metastasis incidence by the TNM stage was scarce.

Objective

This study evaluated the incidence of pulmonary metastasis in colon cancer without synchronous metastasis treated with radical surgery and identified risk factors for pulmonary metastasis according to the TNM stage.

Design and Settings

This retrospective study included all patients with colon cancer without metastasis who underwent radical surgery for primary tumor at Samsung Medical Center between January 2007 and December 2016.

Patients

A total of 4889 patients who underwent radical surgery for stage I and III colon cancer were included.

Main Outcome Measures

The main outcome measures were the incidence of pulmonary metastasis and overall survival.

Results

A total of 156 patients (3.2%) were diagnosed with pulmonary metastasis after a median of 16 months from the time of radical surgery for colon cancer to detection of pulmonary metastasis. The pulmonary metastasis incidence rate by the TNM stage was 0.5% in stage I, 1.6% in stage II, and 6% in stage III. Risk factors for pulmonary metastasis were preoperative CEA > 5ng/mL, cancer obstruction, N stage, vascular invasion, perineural invasion, and adjuvant chemotherapy for primary colon cancer in multivariable analysis.

Limitation

This was a retrospective single-center study.

Conclusions

Preoperative CEA > 5ng/mL, cancer obstruction, pN stage, vascular invasion, perineural invasion, and receiving adjuvant chemotherapy for primary colon cancer were risk factors for pulmonary metastasis in colon cancer. Therefore, patients with risk factors for pulmonary metastasis should be recommended for intensive follow-up to detect lung metastases. See Video Abstract.

Metstasis Pulmonar En El Primer Sitio Tras Ciruga Curativa Del Cncer De Colon Incidencia Y Factores De Riesgo Segn Estadio Tnm

ANTECEDENTES:Los pulmones son uno de los sitios más comunes de metástasis del cáncer de colon. Algunos estudios informaron que aproximadamente entre el 2% y el 10% de los pacientes con cáncer de colon desarrollaron metástasis pulmonar. Sin embargo, entre estos estudios, las características de los pacientes fueron heterogéneas y la información sobre la incidencia de metástasis pulmonares según el estadio TNM fue escasa.OBJETIVO:Este estudio evaluó la incidencia de metástasis pulmonar en cáncer de colon sin metástasis sincrónica tratada con cirugía radical e identificó factores de riesgo para metástasis pulmonar según el estadio TNM.DISEÑO Y AJUSTES:Este estudio retrospectivo incluyó a todos los pacientes con cáncer de colon sin metástasis que se sometieron a cirugía radical por tumor primario en el Samsung Medical Center entre enero de 2007 y diciembre de 2016.PACIENTES:Se incluyó un total de 4.889 pacientes sometidos a cirugía radical por cáncer de colon en estadio I-III.PRINCIPALES MEDIDAS DE RESULTADO:Las principales medidas de resultado fueron la incidencia de metástasis pulmonar y la supervivencia general.RESULTADOS:Un total de 156 pacientes (3,2%) fueron diagnosticados con metástasis pulmonar con una duración media de 16 meses desde el momento de la cirugía radical por cáncer de colon hasta la detección de la metástasis pulmonar. La tasa de incidencia de metástasis pulmonares por estadio TNM fue del 0,5% en el estadio I, del 1,6% en el estadio II y del 6% en el estadio III. Los factores de riesgo de metástasis pulmonar fueron CEA preoperatorio superior a 5ng/ml, obstrucción por cáncer, estadio N, invasión vascular, invasión perineural y quimioterapia adyuvante para el cáncer de colon primario en un análisis multivariable.LIMITACIÓN:Este fue un estudio retrospectivo de un solo centro.CONCLUSIÓN:CEA preoperatorio superior a 5ng/ml, obstrucción por cáncer, estadio pN, invasión vascular, invasión perineural y recibir quimioterapia adyuvante para el cáncer de colon primario fueron factores de riesgo de metástasis pulmonar en el cáncer de colon. Por lo tanto, se debe recomendar un seguimiento intensivo a los pacientes con factores de riesgo de metástasis pulmonares para detectar metástasis pulmonares. (Traducción-Dr Yolanda Colorado).

---

### Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes [^a5e81e0f]. Allergy (2023). Medium credibility.

1 INTRODUCTION

Eosinophilia is observed in a number of inflammatory and other reactive conditions and related disease states, as well as in several hematologic malignancies. In reactive states, eosinophilia is usually a non‐neoplastic process triggered by eosinophil‐targeting cytokines, such as interleukin‐3 (IL‐3) or IL‐5. In contrast, in stem cell‐derived and myeloid neoplasms, eosinophils usually derive from the malignant clone. Reactive eosinophilia may be transient or episodic (recurrent) but may also persist. In contrast, clonal (neoplastic) eosinophilia is always a persistent condition unless the disease progresses to an acute leukemia or specific anti‐neoplastic therapy is introduced. Blood eosinophilia is defined by an absolute eosinophil count (AEC) of more than 0.5 × 10⁹/L, whereas hypereosinophilia (HE) requires an AEC of ≥ 1.5 × 10⁹/L.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^18b2bb63]. Chest (2020). High credibility.

Nonasthmatic eosinophilic bronchitis (NAEB) — initial management: In adult and adolescent patients with chronic cough due to NAEB, we suggest inhaled corticosteroids as first-choice treatment (Grade 2B). Remarks indicate there are very few therapeutic trials in NAEB with small numbers of subjects, making this a weak recommendation.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^f5e1b050]. Chest (2020). High credibility.

CHEST chronic cough due to asthma/NAEB — Question 1 randomized, double-blind, placebo controlled, cross-over study (Chaudhuri et al., 2004) in an outpatient UK setting over 14 days enrolled 88 subjects with cough (13 asthma), age 59.0 ± 12.7, measured FeNO, exhaled CO, sputum eosinophils, and sputum ECP with a cough severity visual analogue scale; in the overall population, Cough VAS improved in response to inhaled corticosteroids, Feno, exhaled CO, and sputum ECP reduced in response to inhaled corticosteroids, Feno, sputum eosinophils, and sputum ECP were predictors of corticosteroid response, and sputum eosinophil % correlated with Feno levels, with the asthma subgroup showing sputum eosinophils reduced in response to inhaled corticosteroids.

---

### Global strategy for asthma management and prevention [^dcdbabe6]. GINA (2024). High credibility.

Severe asthma — evaluation of eosinophilia and parasitic causes: If blood eosinophils are ≥ 300/μL, look for and treat non-asthma causes, including parasites (e.g. Strongyloides serology or stool examination), because parasitic infection may be the cause of the blood eosinophilia and because OCS or biologic therapy in a patient with untreated parasitic infection could potentially lead to disseminated disease; Strongyloides infection is usually asymptomatic. If hypereosinophilia is found, e.g., blood eosinophils ≥ 1500/μL, consider causes such as eosinophilic granulomatosis with polyangiitis (EGPA).

---

### European Respiratory Society guidelines for the diagnosis of asthma in adults [^310895a9]. The European Respiratory Journal (2022). High credibility.

Regarding screening and diagnosis for asthma, more specifically with respect to diagnostic criteria, ERS 2022 guidelines recommend to avoid combining fraction exhaled nitric oxide, blood eosinophils, and serum IgE results to make a diagnosis of asthma.

---

### Practical tips in bronchiectasis for primary care [^5e481cb9]. NPJ Primary Care Respiratory Medicine (2022). Medium credibility.

Clinical suspicion

As has already been mentioned, it is of great importance that the diagnosis of bronchiectasis should not be confused with that of COPD or asthma. The presence of bronchiectasis must be ruled out, independently of any previous diagnosis of COPD or asthma, in any patient with: chronic respiratory symptoms and an underlying disease that causes bronchiectasis; persistent cough especially with usual expectoration (frequently with a purulent or haemoptoic component); chronic rhinosinusitis with productive cough; repeated sputum isolation of pathogenic microorganisms (especially Pseudomomas aeruginosa [PA]); uncontrolled or difficult-to-control COPD or asthma; multiple exacerbations; or recurrent respiratory tract infections. Finally, the presence of allergic bronchopulmonary aspergillosis (a condition also usually associated with bronchiectasis) should be ruled out in patients with uncontrolled asthma.

---

### Global Initiative for Chronic Obstructive Lung Disease 2023 report: GOLD executive summary [^74121008]. American Journal of Respiratory and Critical Care Medicine (2023). Medium credibility.

Diagnosis: Forced Spirometry

A diagnosis of COPD should be considered in any patient who complains of dyspnea, chronic cough or sputum production, a history of recurrent lower respiratory tract infections, and/or a history of exposure to risk factors for the disease (see above), but forced vital capacity maneuver during spirometry showing the presence of a post-bronchodilator FEV₁/FVC ratio < 0.7 is needed to establish the diagnosis of COPD. The FEV₁ also serves to determine the severity of airflow obstruction (GOLD grades 1, 2, 3, 4 or mild, moderate, severe, and very severe). Yet, several important aspects related to forced spirometry need to be considered here.

First, airflow obstruction that is not fully reversible is not specific for COPD. For instance, it may also be found in patients with asthma and other diseases, so the clinical context and risk factors (see above) must also be considered when establishing a diagnosis of COPD.

---

### Gold 2023: highlights for primary care [^f2b83bf5]. NPJ Primary Care Respiratory Medicine (2023). Medium credibility.

New definition

GOLD 2023 defines COPD as a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnoea, cough, expectoration and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction (FEV₁/FVC < 0.7). This definition aims at: (1) recognizing that COPD is heterogeneous; and (2) describing explicitly what are the main structural, functional, and clinical manifestations of the disease.

---

### Diagnostic utility of inflammatory biomarkers in asthma: exhaled nitric oxide and induced sputum eosinophil count [^12166099]. Respiratory Medicine (2007). Low credibility.

Background

Even though an inflammatory process is known to be the underlying cause of asthma, diagnosis is based on clinical history, reversible airway obstruction and bronchial hyperresponsiveness according to international guidelines. The fraction of exhaled nitric oxide (FE(NO)) and induced sputum eosinophil count (Eos%) have been used as non-invasive inflammatory biomarkers.

Objectives

The aim of this study was to compare the sensitivity and specificity of FE(NO), Eos% and spirometry and to assess whether their combined use in clinical practice would improve diagnostic yield.

Methods

In 50 patients with asthma symptoms we performed spirometry, a methacholine challenge test, FE(NO) measurement and assessment of Eos% in induced sputum. The standard diagnosis of asthma followed the guidelines of the Global Initiative for Asthma.

Results

Twenty-two of the 50 patients were diagnosed with asthma. The sensitivity and diagnostic accuracy were higher for FE(NO) measurement (77%; area under the receiver operating curve [AUC], 0.8) than for spirometry (22%; AUC, 0.63). The sensitivity and specificity of Eos% in induced sputum were 40% and 82%, respectively, and the diagnostic accuracy of Eos% was lower (AUC, 0.58). When both inflammatory biomarkers were used together specificity increased to 76%.

Conclusions

The diagnostic accuracy of FE(NO) measurement was superior to that of the standard diagnostic spirometry in patients with symptoms suggestive of asthma. The use of FE(NO) measurement and induced sputum Eos% together to diagnose asthma in clinical practice is more accurate than spirometry or FE(NO) assessment alone and easier to perform.

---

### Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2025 report) [^ae4ce767]. GOLD (2025). High credibility.

Pre- or post-bronchodilator spirometry — diagnostic approach — notes that, in line with other National and International guidelines, GOLD has recommended using post-bronchodilator values when considering a diagnosis of COPD; however, it is now recognised that the bronchodilator response has little value in differentiating asthma from COPD, that pre-bronchodilator values are reproducible, and that obstruction only found on post-bronchodilator measurements is uncommon. Obtaining post-bronchodilator values is more time consuming. Pre-bronchodilator spirometry can be used as an initial test in symptomatic patients, and if it does not show obstruction, performing post-bronchodilator spirometry is not necessary unless there is a very high clinical suspicion of COPD.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^4e53318d]. Chest (2020). High credibility.

CHEST chronic cough due to asthma/NAEB — Question 1 observational study (Takemura et al., 2012) in outpatient Japan over 4 weeks with 23 subjects, age 46 ± 16, assessed sputum eosinophils and cough severity visual analogue scale; cough severity improved with montelukast, sputum eosinophils decreased with montelukast, and change in sputum eosinophils did not correlate with improvement in cough.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^769f6e0c]. Chest (2020). High credibility.

Asthma- and NAEB-related chronic cough — background and prior recommendations — A 10-year follow up evaluation of 12 patients with NAEB suggested that this condition is generally benign and self-limiting, but larger series reported that this condition is rarely self-limiting; in a 4-year retrospective study of 42 patients, seven went into remission and 13 developed classical asthma. In the 2006 CHEST Guideline for chronic cough due to asthma or NAEB, antiinflammatory treatments were recommended as the mainstay of therapy for both conditions, and non-invasive measures of airway inflammation were recommended in patients with suspected NAEB and in patients with asthma whose cough is refractory to initial corticosteroid therapy, although the level of evidence supporting these recommendations was generally low. Non-invasive methods of assessment of airway inflammation (mainly sputum cell counts and FENO) have been included in national and international guidelines on asthma to support its diagnosis but mostly to determine its phenotype to better target therapy, and in this guideline non-invasive methods include blood and sputum cell counts and FENO.

---

### Sodium chromate 51 [^33bd941a]. FDA (2012). Low credibility.

INDICATIONS AND USAGE

Cr51 is indicated for use in determining red blood cell volume or mass, studying red blood cell survival time (in conditions such as hemolytic anemia), and evaluating blood loss

Mechanism of Action

The chromium in this agent is present as the dianionic chromate ion in which form it appears to bind to the red blood cell in two steps, initially by a rapid but reversible attachment to the cell membrane followed by a slower nearly irreversible binding to intracellular hemoglobin and reduction to the anionic state. It has been suggested that the slow rate of uptake is dependent on the rate at which chromate can penetrate the cell membrane. Binding is maintained until the red blood cells are sequestered by the spleen or until elution of the chromium occurs into the plasma. The chromium is then readily excreted mainly in the urine. Once liberated by elution or erythrocyte senescence, chromium 51 is not available for relabeling of red cells.

In normal individuals the erythrocyte survival half-time T ½ as measured by the chromium 51 "random labeling" technique, generally ranges between 25 and 35 days. This apparent short survival time, when compared to the 120 day life span of the red blood cells, is due to the elution of chromium from the cells and to cell damage that probably occurs during the process of withdrawing them from the body and labeling. Subnormal T ½ may be indicative of blood toss, sequestration of red blood cells by the spleen, or shortened cell viability, as occurs In hemolytic anemia

---

### Allergy diagnostic testing: an updated practice parameter [^95e937e6]. Annals of Allergy, Asthma & Immunology (2008). Medium credibility.

Eosinophil-related markers — Eosinophil cationic protein (ECP) measurements have limited clinical utility as an analyte for monitoring patients with extrinsic asthma and other allergic diseases in which eosinophils may play a role in tissue damage, and several eosinophil chemoattractants such as IL-5 and eotaxin are elevated in nasal and BAL samples in patients with active allergic inflammatory disease associated with recent or concurrent exposure to aeroallergens.

---

### Welcome to asthma neverland [^6485c57e]. Pediatric Pulmonology (2025). Medium credibility.

Asthma is a multifactorial disease with heterogeneous clinical and pathophysiological phenotypes. Classical symptoms of asthma are wheeze, cough and breathlessness, and occasionally chest tightness. These symptoms are common to many respiratory and non-respiratory conditions, and misdiagnosis of asthma is frequent. There is no definitive test for the diagnosis of asthma, but a combination of a suggestive medical history, physical examination, lung function tests, and additional investigations will maximize the chances of making a correct diagnosis. Despite clear statements in international asthma guidelines, there are many gaps when performing diagnostic steps in current medical practice. An incomplete medical history, poor attention to the nature of respiratory sounds, failure to carry out objective tests, and inadequate estimation of the response to anti-asthma therapy are the main factors responsible for misdiagnosis of asthma. The use of wrong and potentially dangerous therapies, and high consumption of healthcare resources are the inevitable consequences of misdiagnosis. The main alternative diagnoses to asthma, clinical clues and objective tests useful for specific diagnoses are critically discussed.

---

### Global strategy for asthma management and prevention [^22bfd4b0]. GINA (2024). High credibility.

Asthma — treatment guided by sputum eosinophil count in adults, when compared with guidelines-based treatment, leads to a reduced risk of exacerbations and similar levels of symptom control and lung function in patients with frequent exacerbations and moderate-severe asthma; however, few clinics have routine access to induced sputum analysis, there is insufficient evidence to assess this approach in children, and sputum-guided treatment is recommended for adult patients with moderate or severe asthma who are managed in (or can be referred to) centers experienced in this technique (Evidence A).

---

### Cefaleia em salvas em crianças e adolescentes: uma revis ã o sistemática de relatos de casos [^277ab0fb]. Developmental Medicine and Child Neurology (2021). Medium credibility.

Objetivo

Descrever as características clínicas e as melhores opções terapêuticas para cefaleia em salvas na idade pediátrica. MÉTODO: Com base em pesquisa bibliográfica nas bases de dados médicos PubMed, LiLacs e WoS e usando descritores selecionados, analisamos todos os relatos de casos de cefaleia em salvas em idade pediátrica publicados de 1990 a 2020.

Resultados

Cinquenta e um pacientes (29 meninos e 22 meninas) com idade média (DP) de 9 anos e 7 meses (3 anos e 10 meses), variando de 2 a 16 anos, foram diagnosticados com cefaleia em salvas. O diagnóstico médio (DP) foi feito 27,8 meses (26,2 meses) após o início da cefaleia em salvas. A dor ocorreu à noite ou ao despertar (76,5%), uma a três crises por dia (62,7%), com duração de 30–120 minutos (68,6%), localizada unilateralmente (90,2%), de caráter pulsátil (64,7%) e intensidade severa (100%). Houve manifestações autonômicas (90,2%), predominantemente ipsilaterais à dor, nesta ordem: lacrimejamento, injeção conjuntival, congestão nasal, ptose, edema palpebral e rinorreia. Sumatriptano e inalação de oxigênio foram os tratamentos agudos mais eficazes. Na profilaxia, corticosteroides, verapamil e gabapentina foram os medicamentos mais eficazes. INTERPRETAÇÃO: Devido ao pequeno número de estudos publicados, esta revisão não foi capaz de fornecer dados confiáveis, mas parece que a cefaleia em salvas em crianças e adolescentes é semelhante à do adulto, tanto nas características clínicas quanto no tratamento.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^21dcfa03]. Chest (2020). High credibility.

Asthma/NAEB background — epidemiology, diagnostic testing, and inflammatory markers: Asthma affects more than 300 million people worldwide and multiple prospective studies have shown that between 24% and 32% of chronic cough in adult non-smokers is related to asthma. In suspected asthma causing chronic cough with non-diagnostic examination and spirometry, bronchial challenge testing (eg, methacholine inhalation test) should be performed to confirm airway hyperresponsiveness. Non-invasive inflammatory markers such as blood or sputum eosinophil counts and fractional exhaled nitric oxide (FENO) can provide additional evidence to support the need for corticosteroid treatment. In cohorts where airway inflammation is assessed, NAEB accounts for 10% to 30% of cases referred for specialist investigation.

---

### Exhaled nitric oxide measurement is useful for the exclusion of nonasthmatic eosinophilic bronchitis in patients with chronic cough [^7d7279a0]. Chest (2008). Low credibility.

Background

Nonasthmatic eosinophilic bronchitis (NAEB) is an important cause of chronic cough, and it can be diagnosed by an induced-sputum (IS) examination. However, an IS examination is a complex and time-consuming procedure, and it has limited clinical application. This study aimed to evaluate the role of exhaled nitric oxide (NO) for the investigation of chronic cough, especially of NAEB.

Methods

Two hundred eleven nonsmoking patients with a cough lasting > 3 weeks were enrolled in the study. The patients were examined and investigated with conventional diagnostic tools, including an IS examination. Exhaled NO was measured by a chemoluminescent analyzer.

Results

One hundred seventeen patients with adequate IS results were analyzed: asthma, n = 14; NAEB, n = 21; and "others", n = 82. Exhaled NO and IS eosinophils were significantly higher in the asthma group and NAEB group than in the others group. Exhaled NO and IS eosinophils were significantly correlated in the asthma and NAEB groups. In the nonasthmatic group, the sensitivity and specificity of exhaled NO for detecting NAEB, using 31.7 parts per billion as the exhaled NO cutoff point, were 86% and 76%, respectively. Positive and negative predictive values were 47% and 95%, respectively, and positive and negative likelihood ratios were 3.51 and 0.19, respectively.

Conclusion

We concluded that exhaled NO measurement may be useful as part of the initial evaluation for chronic cough, especially for the exclusion of NAEB. A low level of exhaled NO suggested little likelihood of NAEB for the nonasthmatic patients with chronic cough.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^f7ac2732]. Chest (2020). High credibility.

Asthma-related cough — non-invasive airway inflammation measures: The included studies were judged at low risk of bias in five of the seven domains, sample sizes were small, and a favorable response to inhaled corticosteroids (ICS) was predicted by sputum eosinophil count, sputum eosinophil cationic protein concentration, and FENO, whereas responses to montelukast and zafirlukast were not related to airway inflammation when assessed with non-invasive measures.

---

### Eosinophilic bronchitis: clinical manifestations and implications for treatment [^1cbd79a3]. Thorax (2002). Low credibility.

Airway inflammation with eosinophils is now reported to occur not only in asthma but in other airway diseases such as cough variant asthma, chronic cough, atopic cough, episodic symptoms without asthma, allergic rhinitis, and COPD. Although the prevalence of eosinophilic bronchitis (EB) is less than in asthma, the causes, mechanisms and treatment of EB in these conditions appears to be similar to asthma where allergen induced IL-5 secretion and symptoms are readily responsive to inhaled corticosteroids. The prognosis of EB without asthma is not known but it may be a precursor for asthma and, if so, recognition of this syndrome may permit effective treatment and reduction in the rising prevalence of asthma. Induced sputum analysis allows recognition of EB in clinical practice. The place of the asthma treatment paradigm with early and sustained corticosteroid treatment needs to be defined in EB without asthma. Airway wall remodelling can occur in rhinitis, COPD, and cough variant asthma with EB. The mechanisms and long term implications of this complication in EB without asthma need to be clarified.

---

### Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes [^5607ab9b]. Allergy (2023). Medium credibility.

6 OF UNKNOWN SIGNIFICANCE

When no familial clustering, underlying pathology, related molecular (genetic) abnormalities, or HE‐related organ damage is found in a patient presenting with HE, the provisional diagnosis "HE of unknown significance" (HE US) should be considered (Table 2, Figure 1). A diagnosis of HE US requires (a) exclusion of an underlying disease or condition that can induce HE and (b) exclusion of HES. Close follow‐up of patients with HE US is essential, since eosinophil‐related organ damage may develop after several months to years, and/or an underlying disease may become apparent over time with additional diagnostic testing. Should either of these occur, the diagnosis will change to another form of HE or HES (Figure 1). Finally, mild eosinophilia (0.5–1.5 × 10⁹/L) not meeting criteria of HE may be associated with organ dysfunction or organ damage, and should, therefore, prompt the physician to initiate in‐depth investigations.

---

### Does the routine use of spirometry improve clinical outcomes in children? – A systematic review [^8458cbb8]. Pediatric Pulmonology (2022). Medium credibility.

2.3 Study design

We included all randomized controlled trials (RCTs) and quasi‐RCTs. We excluded studies not published in English, case reports, and studies published in abstract only.

2.4 Information sources

Literature searches were undertaken within PubMed, Embase, Cochrane Central Register of Controlled Trials, US National Institutes of Health Ongoing Trials Register, and World Health Organization International Clinical Trials Registry Platform. Reference lists of included primary studies were hand searched for additional relevant references.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^bd257a3e]. Chest (2020). High credibility.

Question 3 population, intervention, comparison, outcome flow diagram — study selection counts are detailed: articles identified through database searching were 134 with 0 additional sources; 134 records were screened after duplicates; 98 were excluded by title or abstract; 36 full texts were assessed; 30 full texts were excluded with reasons (6 not about treatment, 7 other than NAEB, 17 review articles or case reports); and 6 articles were included in the systematic review.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^eb97a996]. Chest (2020). High credibility.

Non-asthmatic eosinophilic bronchitis (NAEB) chronic cough — management when response to ICS is incomplete: In adult and adolescent patients with chronic cough due to NAEB, if response to inhaled corticosteroids (ICS) is incomplete, we suggest stepping-up the inhaled corticosteroid dose and considering a therapeutic trial of a leukotriene inhibitor after reconsideration of alternative causes of cough (Grade 2C). Remarks note very few therapeutic trials with small numbers of subjects, making this a weak recommendation.

---

### Unresponsive wheezing to asthma therapy in a 32-year-old female [^58116aa1]. Annals of Allergy, Asthma & Immunology (2003). Low credibility.

Repeat failure of any patient to respond to asthma therapy, particularly corticosteroids, should alert physicians to carry out further pulmonary evaluation. This will prevent unnecessary side effects of asthma therapy and provide prompt treatment for other diseases that may require urgent attention.

---

### Proceedings of the 29th European paediatric rheumatology congress [^9594c410]. Pediatric Rheumatology Online Journal (2023). Medium credibility.

P163 Pediatric eosinophilic granulomatosis with polyangiitis responding to mepolizumab: case report

R. Escamilla 1, A. Arellano 1, A. Tlacuilo 1, A. Delgado 2

1 Pediatric Rheumatology; 2 Pathology, UMAE Hospital de Pediatría CMNO, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico

Correspondence: R. Escamilla

Pediatric Rheumatology 2023, 21(Suppl 2): P163

Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic vasculitis, characterized by history of asthma and allergies affecting ears, nose and airway, associated with positivity to antineutrophil cytoplasmic autoantibodies (ANCA) in 30–40%. EGPA treatment in pediatrics is based on the use of corticosteroids and disease-modifying antirheumatic drugs. Mepolizumab, an anti-interleukin-5 monoclonal antibody, reduces blood eosinophil counts and may have value in the treatment of EGPA.

Objectives: To report a case of pediatric EGPA, on treatment with Mepolizumab.

Methods: The patient's data and relevant photographs of studies were collected of the clinical record. A review of the literature was made with articles from indexed medical journals.

Results: A 10-year-old female presented to the Pediatric Rheumatology department with chronic cough and multiple hospitalizations due to pneumonic infections since 2 years old. Afterwards she developed noisy breathing and was diagnosed with allergic rhinitis and hard control asthma by the age of 5 years, the patient was referred due to persisting lung infiltrates on chest radiograph and eosinophilia. Laboratory testing corroborated the presence of eosinophilia > 1000/L in multiple determinations and elevated acute phase reactants, however ANCA were negative. A high resolution computed tomography scan of the lungs showed dense infiltrates; therefore the patient underwent bronchoscopy with tracheal biopsy, showing necrosis and perivascular inflammatory infiltrate within the endothelium, integrating an EGPA diagnosis.

The patient was started on Prednisone and Cyclophosphamide as induction therapy followed by Methotrexate as maintenance during two years, without significant improvement, persisting with exacerbations of asthma, requiring multiple hospitalizations and use of supplementary oxygen, since 7 years-old.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^27c4bbde]. Chest (2020). High credibility.

Non-asthmatic eosinophilic bronchitis (NAEB) chronic cough — initial therapy: In adult and adolescent patients with chronic cough due to non-asthmatic eosinophilic bronchitis (NAEB), we suggest inhaled corticosteroids (ICS) as first-choice treatment (Grade 2B).

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^ead1816a]. Chest (2020). High credibility.

Question 2 study selection — articles identified through database searching (n = 622) plus additional articles from other sources or not initially screened (n = 34) were processed; after duplicates were deleted, articles screened totaled (n = 656), with articles excluded from the title or abstract (n = 493), and full-text articles assessed for eligibility (n = 163); full-text articles excluded, with reasons (n = 110), included 15 = age < 13 y, 8 = language other than English, 42 = not about cough, 6 = not about treatment, 6 = other than asthma, and 33 = other reason; articles included in the systematic review were (n = 53).

---

### Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's disease neuroimaging initiative… [^ae3c8817]. JAMA Network (2025). Excellent credibility.

We compared MCI and AD patients enrolled in ADNI who were receiving ChEIs and memantine with those who were not receiving those medications on clinical differences at study entry and outcomes over 2 years to assess the medications' potential for efficacy or for affecting clinical outcomes. Mild-cognitive-impairment patients treated with ChEIs only or with ChEI and memantine showed decline on the ADAS-cog, MMSE, CDR-SB, and FAQ to a greater extent than patients not receiving those medications. The mean differences generally increased from month 6 to month 24. Duration of exposure to ChEI treatment prior to study entry was not associated with change on the ADAS-cog compared with no treatment. However, every year of ChEI exposure prior to study entry was associated with a rate of decline of 0. 13 point per year slower on the CDR-SB,
0. 12 point per year slower on the MMSE, and 0. 41 point per year slower on the FAQ compared with no treatment. Sixteen of 177 MCI patients taking ChEIs discontinued treatment during follow-up, and 45 of 215 not taking ChEIs started to do so. Five of 36 patients taking memantine at baseline discontinued doing so. Of 356 not taking memantine at baseline, 45 started doing so, with 29 taking it in addition to their ChEI. Duration of exposure prior to entry was not associated with change on the ADAS-cog, MMSE, CDR-SB, or FAQ among AD patients treated only with a ChEI vs treatment with both types of medication.

from American Academy of Neurology, BOLT International, GE Healthcare Japan, Institut Català de Neurociencias Aplicades, Ipsen, The Johns Hopkins University, NeuroVigil Inc, the Rotman Research Institute, and the Research Institute for Biotechnology; serves as a consultant for Araclon Biotech, AstraZeneca.

---

### Occupational and environmental contributions to chronic cough in adults: chest expert panel report [^91e9872e]. Chest (2016). Medium credibility.

Asthma and nonasthmatic eosinophilic bronchitis (NAEB) — prevalence and allergic evaluation: Prospective studies show asthma is among the most common etiologies of chronic cough (24%-29%) in adult nonsmokers, and in some patients the only symptom and finding is cough (cough-variant asthma). Diagnosis is via spirometry that may show expiratory obstruction with significant β2-adrenergic response or normal baseline spirometry with increased airway responsiveness to methacholine. NAEB was identified in 13.2% of those with chronic cough; diagnosis requires proof of airway eosinophilia determined by sputum induction or bronchial wash fluid obtained by bronchoscopy. NAEB patients demonstrate atopic tendencies with elevated sputum eosinophils and increased IL-5 gene expression, and allergens and occupational exposures have been reported as causes of NAEB-related cough. Given allergic mechanisms, clinicians caring for such patients must be familiar with allergy diagnostic testing, recognizing that skin and serum-specific IgE tests can be positive without clinical relevance and must be interpreted in the context of clinical history.

---

### Theophylline anhydrous (Theo-24) [^20ecdd82]. FDA (2024). Medium credibility.

INDICATIONS AND USAGE

Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^50466f70]. Chest (2020). High credibility.

CHEST guideline — Recommendation 2 for chronic cough due to asthma/cough variant asthma (CVA) in adults and adolescents states: In adult and adolescent patients with chronic cough due to asthma as a unique symptom (CVA), we suggest that inhaled corticosteroids (ICS) should be considered as first line treatment, and if response is incomplete in those with CVA or if cough remains isolated after treatment with inhaled corticosteroids in asthma, we suggest stepping-up the inhaled corticosteroid dose and considering a therapeutic trial of a leukotriene inhibitor after reconsideration of alternative causes of cough; beta-agonists could also be considered in combination with ICS (Grade 1B). The evidence base supporting the step-wise treatment for asthma is very strong, and the grade thus reflects the very strong evidence for step-wise treatment of asthma in general rather than specifically for cough.

---

### Practical tips in bronchiectasis for primary care [^7fbe6f31]. NPJ Primary Care Respiratory Medicine (2022). Medium credibility.

Introduction

Asthma and chronic obstructive pulmonary disease (COPD) are the most common chronic inflammatory airway diseases. They have been estimated to affect more than 5–10% of the world population –. Although both asthma and COPD remain clearly underdiagnosed, it is very important to consider that they are not the only existing chronic inflammatory airway diseases that can be clinically suspected in Primary Care, and therefore a good differential diagnosis must be made with respect to other entities. It must be borne in mind that a diagnosis is not necessarily always going to be COPD (or only COPD) in a male smoker with airflow obstruction, or asthma (or only asthma) in a non-smoking female with airflow obstruction, even though these diagnoses are correct most of the time. It is always necessary to think that these same symptoms and signs can appear in other airway diseases, and if these are correctly diagnosed a patient's follow-up and treatment may have to be altered.

Bronchiectasis is the third most common chronic inflammatory airway disease, after COPD and asthma. Its prevalence is not known, but it is estimated to be around 350–500 cases/100,000 inhabitantsand it increases rapidly with age. Its symptoms can easily be confused with those of COPD and asthma. Bronchiectasis can be caused by dozens of pulmonary and extra-pulmonary diseases (although in up to 30–50% of cases the cause is unknown), and, as in COPD and asthma, a variable number and severity of exacerbations can appear throughout its natural history, usually with an infectious profile. A global consensus of experts recently defined bronchiectasis as a clinical-radiological disease consisting of dilation of the bronchial lumen accompanied by compatible symptoms (usually chronic cough plus expectoration with a purulent component). This dilation of the bronchial lumen is produced by a vicious circle of inflammation and chronic infection that injures the bronchial wall, producing irreversible destruction. Bronchial inflammation and infection are therefore two key points in the management of these patients –, and, as in COPD and asthma, chronic airflow obstruction is their most frequent functional pattern. In severe cases, systemic inflammation, (predominantly neutrophilicbut sometimes with a significant eosinophilic profile) is present –. In this article, we will try to offer a series of important concepts (Box 1) and practical tips (Box 2) on the diagnosis and management of bronchiectasis in Primary Care. However, it is important to highlight that these recommendations could vary according to the geographical area and the resources available in each respective setting.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^1cb24d22]. Chest (2020). High credibility.

Nonasthmatic eosinophilic bronchitis (NAEB) — when response to ICS is incomplete: In adult and adolescent patients with chronic cough due to NAEB if response to ICS is incomplete, we suggest stepping-up the inhaled corticosteroid dose and considering a therapeutic trial of a leukotriene inhibitor after reconsideration of alternative causes of cough (Grade 2C). Remarks note very few therapeutic trials in NAEB with small samples, making this a weak recommendation.

---

### Developing a standardized approach for assessing mast cells and eosinophils on tissue biopsies: a Work group report of the AAAAI allergic skin diseases committee [^2164b4a6]. The Journal of Allergy and Clinical Immunology (2021). High credibility.

Eosinophil and mast cell degranulation — both cell types can degranulate, which affects technical detection and counting in biopsies; immunohistochemistry (IHC) for eosinophil granule proteins can reveal extracellular degranulation even when intact eosinophils are not seen, and despite established cutoffs in eosinophilic esophagitis, this caveat still needs to be considered in other eosinophil- and mast cell–mediated diseases.

---

### Will nonasthmatic eosinophilic bronchitis develop into chronic airway obstruction? a prospective, observational study [^4a120c17]. Chest (2015). Low credibility.

Objective

The long-term prognosis of nonasthmatic eosinophilic bronchitis (NAEB) is still unclear. The aim of this study was to observe the frequency of relapse among patients with NAEB and the likelihood of NAEB developing into chronic airflow obstruction over time.

Methods

Patients with NAEB were followed for at least 1 year between 2003 and 2013. During this period, we evaluated clinical symptoms, sputum eosinophil count, spirometry, and bronchial hyperresponsiveness. A linear mixed model was adopted to determine the relationship between time and lung function.

Results

A total of 234 patients with NAEB were identified, of whom 141 were followed for > 1 year (median, 4.1 years). Up to 59.6% of patients had a relapse after treatment. Both allergic rhinitis (OR, 4.37; 95% CI, 1.049–18.203; P = 0.043) and sputum eosinophilia after 4 weeks of treatment with inhaled corticosteroids (OR, 9.493; 95% CI, 2.381–37.850; P = 0.001) were risk factors for relapse. Among the 141 patients, mild asthma developed in eight (5.7%). During the follow-up period, no progressive decline in FVC, FEV₁, and FEV₁/FVC were observed (P > .05). Although the proportion of small airway dysfunction (maximum midexpiratory flow [MMEF] < 65%) significantly increased at the last visit in all groups (all P < .05), only the relapse group showed an MMEF decline at the end of follow-up (P < .05) in the linear mixed model.

Conclusions

More than 50% of patients with NAEB have repeated episodes associated with persistent sputum eosinophilia after treatment and allergic rhinitis. In the current cohort, chronic airway obstruction does not develop despite small airway dysfunction increases over time.

---

### Eosinophilia in infectious diseases [^f31db422]. Immunology and Allergy Clinics of North America (2015). Low credibility.

In determining the etiology of eosinophilia, it is necessary to consider the type of patient, including previous travel and exposure history, comorbidities, and symptoms. In this review, we discuss the approach to the patient with eosinophilia from an infectious diseases perspective based on symptom complexes.

---

### Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2025 report) [^f9b1b6d5]. GOLD (2025). High credibility.

Chronic obstructive pulmonary disease (COPD) — differential diagnosis emphasizes that, in some patients with COPD, distinguishing COPD from asthma is difficult using current imaging and physiological testing techniques because the two conditions share common traits and clinical expressions, whereas most other potential differential diagnoses are easier to distinguish from COPD.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^25fe3cb6]. Chest (2020). High credibility.

Cough variant asthma (CVA) treatment in chronic cough — stepwise pharmacotherapy: In adult and adolescent patients with chronic cough due to asthma as a unique symptom (cough variant asthma [CVA]) we suggest that inhaled corticosteroids should be considered as first line treatment. If response is incomplete in those with CVA or if cough is the remaining isolated symptom following treatment with inhaled corticosteroids in patients with asthma in whom cough was one of their symptoms we suggest stepping-up the inhaled corticosteroid dose and considering a therapeutic trial of a leukotriene inhibitor after reconsideration of alternative causes of cough. Beta-agonists could also be considered in combination with inhaled corticosteroids (ICS) (Grade 1B).

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^cabf6b41]. Chest (2020). High credibility.

Cough due to nonasthmatic eosinophilic bronchitis (NAEB) — treatment evidence scope: The studies included in this systematic review are summarized in Table 8.

---

### Corticosteroid therapy for sepsis: a clinical practice guideline [^c5715ba9]. BMJ (2018). Excellent credibility.

Updates to this article

The final table shows evidence that has emerged since the publication of this article. As new evidence is published, a group will assess the new evidence and make a judgment on to what extent it is expected to alter the recommendation.

New evidence which has emerged after initial publication

---

### Development of chronic airway obstruction in patients with eosinophilic bronchitis: a prospective follow-up study [^00caa679]. Chest (2004). Low credibility.

Study Objectives

Eosinophilic bronchitis (EB) presents as a chronic cough and sputum eosinophilia without airflow limitation or bronchial hyperreactivity. Its long-term clinical course remains unknown. This study evaluated how frequently EB recurs and whether it develops chronic airway obstruction.

Design

This study was a prospective analysis.

Methods

Cough severity, FEV₁, provocative concentration of methacholine causing a 20% fall in FEV₁, and sputum eosinophil percentages were serially measured in 36 subjects for up to 48 months. All subjects inhaled corticosteroids until cough subsided.

Results

Five of the twenty four follow-up subjects (21%) had a recurrent episode of EB 4 to 6 months after disappearance of the first episode of EB (recurrent eosinophilic bronchitis). Progressive FEV₁ reduction > 20% was observed in three of the subjects, including a subject with asthma developing at the ninth month. Nineteen subjects had no recurrence of cough (nonrecurrent eosinophilic bronchitis) and no progressive FEV₁ reduction > 20%. However, sputum eosinophilia recurred between 4 months and 24 months in 10 subjects. Mean values of FEV₁ at the ninth and 12th months of the study were significantly lower in the recurrent eosinophilic bronchitis group than in the nonrecurrent eosinophilic bronchitis group (p < 0.01).

Conclusion

These results suggest that repeated episode of EB is associated with the development of chronic airflow obstruction, including asthma.

---

### Secondhand smoke exposure and quality of life in patients with heart failure… [^acc552c1]. JAMA Network (2011). Excellent credibility.

Methods Current nonsmokers with heart failure were enrolled in a cohort study. Exposure to SHS was assessed with a validated exposure questionnaire and a high-sensitivity assay for urinary cotinine level. An improved assay with a lower limit of detection of 0. 05 ng/mL was introduced partway through the study. For the purposes of this analysis, individuals with urinary cotinine determinations higher than 50 ng/mL were excluded as probable smokers, 9 resulting in a final sample of 202 patients. For analyses of the relationship between urinary cotinine level and HRQOL measures, participants were considered to have no SHS exposure if urinary cotinine level measured less than 0. 2 ng/mL. This cut point was chosen because it was the lower limit of detection for the high-sensitivity cotinine assay used at the start of the study. The mean urinary cotinine level in patients who reported no exposure to SHS was 0. 26 ng/mL; the mean level in those with reported exposure was

1. 43 ng/mL. The relationship between self-reported exposure and urinary cotinine level is shown in the Figure. There was a trend for increasing quartiles of urinary cotinine level to be associated with a 3. 78-point drop in role physical scores after adjustment for age, sex, NYHA class, and comorbidity scores. Urinary cotinine level was also associated with a 1. 48-point decrement per quartile in role emotional scores; however, this did not reach statistical significance after adjustment for clinical factors. All variables in the multivariate models had variance inflation factors of less than 1. 5, suggesting there is no significant multicollinearity. Directly measured SHS exposure, as classified by urinary cotinine level, was associated with increased severity and worse disease-specific HRQOL in patients with chronic obstructive pulmonary disease.

19 In the pediatric population, randomization to a school-based asthma treatment program was associated with improved parent and caregiver. Thus, there are several mechanisms by which SHS could exert a detrimental effect on outcomes and ultimately on HRQOL.

---

### Clinical and inflammatory features of asthma with dissociation between fractional exhaled nitric oxide and eosinophils in induced sputum [^dbbfe29c]. The Journal of Asthma (2016). Low credibility.

Background

Measurement of the fractional exhaled nitric oxide (FeNO) and eosinophils in induced sputum are noninvasive markers for assessing airway inflammation in asthma. The clinical usefulness of the correlation between raised FeNO and sputum eosinophilia is controversial. We aimed to examine dissociation between FeNO and sputum eosinophils in a clinical series of asthma patients and to determine whether dissociation between these noninvasive markers was associated with clinical and inflammatory differences in these patients.

Methods and Findings

A total of 110 patients with asthma were included in a cross-sectional study. All of them were on maintenance treatment for asthma. All patients underwent the following on the same day: FeNO, induced sputum, spirometry, serum total IgE levels and skin prick test. The level of asthma control was determined by the Asthma control Test Questionnaire. In 46 (41.8%) patients, a discrepancy between FeNO and sputum eosinophil count was observed, of those, 34 (73.9%) had a FeNO < 50ppb and high eosinophil count, and were characterized by having a predominance of nonallergic asthma with bronchial eosinophilic inflammatory phenotype. Also, 12 (26.1%) patients had FeNO ≥ 50ppb and sputum eosinophilia within the normal reference values, and were characterized by having a predominance of atopy with a paucigranulocytic inflammatory phenotype.

Conclusions

A high percentage of patients with dissociation between results of FeNO and sputum eosinophils was observed. These patients showed differential clinical and inflammatory features.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^3cfb964a]. Chest (2020). High credibility.

Question 2 observational trials with no comparator — beta2-agonists for chronic cough due to asthma or nonasthmatic eosinophilic bronchitis describe: an observational primary-care German cohort treated for 4 weeks with formoterol at physicians' discretion (subjects 2,727; mean age 50 ± 18; male 1,445); an outpatient UK observational series over 4 weeks in 21 subjects using salbutamol PRN or terbutaline 0.5 mg PRN with days per week with cough ↔; and a randomized, double blind, parallel group, placebo controlled study without statistical comparison to placebo over 12 weeks (21 subjects; age 29; 38% male) using salbutamol 3 mg QID with cough score ↓ and sleep disturbance score ↓ compared with baseline.

---

### An international ISHLT / ATS / ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome [^7ebbb0ae]. The European Respiratory Journal (2014). Low credibility.

The disease bronchiolitis obliterans syndrome can be associated with ↓ FEV1, wheezing, HSCT, crackles, bronchiectasis, dry cough, fatigue, obstructive spirometry pattern, ↓ breath sounds, lung transplantation and dyspnea.

---

### JAMA oncology peer reviewers in 2024… [^582353ee]. JAMA Network (2025). Excellent credibility.

Karla V. Ballman Fiyinfolu Oladele Balogun Heejung Bang Ramon F. Barajas Pedro Coelho Barata Emma L. Barber William E. Barlow Regina Barragan-Carrillo Jemar Bather Prashant Bavi. Richard J. Bleicher Jeffrey Bogart Jean Marie Boher Alberto Bongiovanni Michael A. Bookman Christopher M. Booth Prithviraj Bose Patrick T. Bradshaw Alain Braillon Dejana Braithwaite Gabriel A. Brooks James B. Brugarolas. Ashley Bryant Chakra Budhathoki Harry B. Burke William M. Burke Timothy Burns Eric Burton Yuh-Pey Anne Buu Marc Buyse Kushinga Bvute Maria E. Cabanillas Gregory Sampang Calip David Cameron Quy Cao. Oliver Dorigo Lucas Vieira dos Santos Fahima Dossa Rodney L. Dunn Urshila Durani Michael Dykstra E Issam El Naqa Areej El-Jawahri Mark Emberton Daniel Evan Epner Narendranath Epperla. Yaacov Richard Lawrence Choong-kun Lee J. Jack Lee Jeannette Lee Jung-Min Lee Joshua Levy Fang-Yong Li Zhongxing Liao Stuart Lichtman Jakob Liermann Joao Paulo da Silveira Nogueira Lima. Thomas W. Lycan Gary H.

Lyman Jennifer W. Mack Sham Mailankody Raymond H. Mak Brandon J. Manley. Francesco Perrone Kelly-Anne Phillips Jin Piao Luke R. G. Pike Laura C. Pinheiro Chelsea Camille Pinnix Katherine L. Pogue-Geile Seth M. Pollack Olena Polyakova Chris Porter Katharine A. Price Daniel A. Pryma. Brian I. Rini Kirsty P. Robledo Flavio G. Rocha Cristina Rodriguez Carlos A. Rodriguez-Russo Rafael Rosell Shoshana M. Rosenberg Ashley E. Ross Olivier Rouvière Upal Basu Roy Larry Rubinstein.

---

### Type 2 immunity-driven diseases: towards a multidisciplinary approach [^449e9981]. Clinical and Experimental Allergy (2021). Medium credibility.

TABLE 3
Unmet needs in type 2‐driven diseases

Another issue to be settled is the relevance of assessing type 2 inflammation involvement with biomarkers. A biomarker is a molecule, a gene or a characteristic that is linked to a specific diagnosis, prognosis or response to treatment. To be useful, a biomarker must be not only relevant and consistent but also specific and easy to use. Dealing with type 2 inflammation assessment in clinical practice, 2 situations must be emphasized. First, a clinician should be able to recognize type 2 involvement in individual settings. Second, tools should be available to help the clinician choose the best specific treatment for the patient.

In asthma, type 2 extended evaluation is principally done in rare severe forms of the disease (4% of the adult asthma population) due to the complex procedure involved and the cost of the biotherapies. However, such consideration must be tempered, as research on an allergic component has long been part of asthma healthcare strategies (avoidance of allergens, AIT). Phenotyping and endotyping of asthma of any severity is an important objective to improve our knowledge of the natural course of the disease and also its treatment. Consensual eosinophilic severe asthma definition was proposed by a European Respiratory Society taskforce based on a combination of major and minor criteria. This definition is based mainly on 3 biomarkers: sputum induction, blood eosinophilia and F ENO (exhaled nitric fraction). Sputum induction is considered to be the gold standard of inflammation evaluation in asthma. However, this technique requires trained operators and pathologists, lacks standardization and is also restricted to specialized expert centres. Recent guidelines from the European Respiratory Society and American Thoracic Society recommend assessing blood eosinophilia and F ENO at the expense of sputum induction. Nevertheless, it should be bear in mind that the correlations among blood eosinophilia, F ENO, eosinophilic infiltration and symptoms are far from perfect. Conversely, with such obstacles to ensure the strong endotyping of patients, robust biomarkers for the prediction of the response to biotherapies are still lacking. Even though correlations between blood eosinophilia and the response to anti‐IL5 strategies have been separately reported, there are still unexpected non‐responders.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^e8ea7098]. Chest (2020). High credibility.

Regarding specific circumstances for chronic cough, more specifically with respect to patients with non-asthmatic eosinophilic bronchitis, ACCP 2020 guidelines recommend to consider initiating ICSs as first-line therapy in adult and adolescent patients with chronic cough due to non-asthmatic eosinophilic bronchitis.

---

### Diagnostic possibility of the combination of exhaled nitric oxide and blood eosinophil count for eosinophilic asthma [^a85e509c]. BMC Pulmonary Medicine (2021). Medium credibility.

Overlap between asthma patients and normal or elevated biomarkers

Based on cutoff values selected for these two biomarkers (FeNO, 40 ppb; B-Eos, 300 cells/μl), we classified the 2349 patients into four groups: group A (high FeNO, high B-Eos count), group B (high FeNO, low B-Eos count), group C (low FeNO, high B-Eos count), and group D (low FeNO, low B-Eos count). The overlap between asthmatic patients and increased FeNO or B-Eos count is shown in Fig. 4 A. The overall chi-square test between the four groups showed statistical differences, and there were also significant differences in the proportion of asthma patients between any two of the four groups (Fig. 4 B, all P < 0.001). Asthma patients accounted for 82.8% of group A, while in group D the proportion of asthma patients was the lowest at 17.8%.

---

### Risk factors associated with the detection of pulmonary emphysema in older asymptomatic respiratory subjects [^f52504f4]. BMC Pulmonary Medicine (2020). Medium credibility.

Conclusions

This study reveals that a small but significant percentage of older, respiratory asymptomatic individuals present emphysematous lesions that may be diagnosed earlier mainly if they have a history of smoking and a family history of lung diseases.

---

### Cough in hypereosinophilic syndrome: case report and literature review [^647c754f]. BMC Pulmonary Medicine (2020). Medium credibility.

Background

Chronic cough is defined as the sole or predominant symptom and lasting for more than 8 weeks, with a normal chest x-ray. The common causes of chronic cough are cough-variant asthma (CVA), non-asthmatic eosinophilic bronchitis (NAEB), upper airway cough syndrome and gastroesophageal reflux disease (GERD). Eosinophilic airway inflammation is commonly observed in chronic cough, usually responding to corticosteroids.

Recently, two outstanding reviews describe the emerging role of eosinophilic inflammation in chronic cough, new insights on its mechanisms and available treatments. These two reviews basically focused on eosinophilic airway inflammation in asthma, nonasthmatic eosinophilic bronchitis, and upper airway cough syndrome. However, the hypereosinophilic syndrome (HES) could be a rare and long-ignored cause of chronic cough. HES comprises a heterogeneous group of hematologic disorders characterized by unexplained sustained eosinophilia (> 1500/μL for more than 6 months) associated with signs and symptoms of organ involvement. While HES is a rare disease, HES presenting with chronic cough as the main symptom is even rarer. HES patients may have eosinophilic infiltrates in the airways, and are often misdiagnosed as CVA, asthma, or other eosinophilic lung diseases. Chronic cough as presenting manifestation of platelet-derived growth factor receptor alpha (PDGFRA) + chronic eosinophilic leukaemia is being increasingly recognized. Recently, we successfully treated 2 patients with HES, eosinophilic airway inflammation, and chronic cough, in whom one was PDGFRA +, but the other was not. We report both cases and reviewed all published cases and cohorts in literature to learn more about the features of HES-associated cough.

---

### Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis [^bb25fb8c]. Allergy (2002). Low credibility.

Background

Eosinophils and T lymphocytes represent constant features in the airways of subjects with exacerbated chronic bronchitis. Eotaxin is the most potent and selective eosinophil chemoattractant which can also attracts lymphocytes. The aim of the study was to evaluate the expression of eotaxin and its receptor, CCR3, in bronchial airways during exacerbation of chronic bronchitis.

Methods

By immunohistochemistry we studied eotaxin and CCR3 expression in the lamina propria of 14 subjects with acute exacerbation of chronic bronchitis. 20 asthmatics, and 8 healthy subjects. We determined the cell types expressing the CCR3 receptor by colocalization experiments. We finally studied the relationship between eotaxin and CCR3 and eosinophils and T lymphocytes.

Results

The number of eotaxin+ and CCR3+ cells was significantly higher in exacerbated chronic bronchitis (P < 0.003 and P < 0.002) and asthma (P < 0.002 and P < 0.0001) when compared to healthy subjects. CCR3 was mainly expressed by eosinophils and to a lesser extent by CD4+ and CD8+ lymphocytes. In exacerbated chronic bronchitis the number of CCR3+ cells was strongly correlated to the number of eosinophils (P < 0.0002. r = 0.85) and to the number of CD4+ lymphocytes (P < 0.05, r = 0.57).

Conclusion

Our study suggests that eotaxin and CCR3 are up-regulated and could be involved in the eosinophil and CD4+ lymphocyte recruitment into the airways which occur during acute exacerbations of chronic bronchitis.

---

### Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2025 report) [^73af8df3]. GOLD (2025). High credibility.

Alpha-1 antitrypsin deficiency (AATD) screening in COPD — "The World Health Organization recommends that all patients with a diagnosis of COPD should be screened once for AATD, especially in areas with high AATD prevalence". The phenotype description states, "Although the classical patient is young (< 45 years) with panlobular basal emphysema, it has become recognized that delay in diagnosis has led to identification of some AATD patients when they are older and have a more typical distribution of emphysema (centrilobular apical)". A laboratory indicator is that "A low concentration (< 20% normal) is highly suggestive of homozygous deficiency".

---

### Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD) [^8f1c4196]. Respiratory Medicine (2013). Low credibility.

Aim

To determine the prevalence and analyze the most relevant clinical characteristics of three clinical phenotypes of COPD: emphysema (type 1), chronic bronchitis (type 2) or COPD-asthma (type 3).

Method

Observational, multicenter study performed with 331 COPD patients recruited in pulmonology outpatient services. The stratification in three phenotypes was performed with imaging tests, pulmonary function, and a standardized clinical questionnaire.

Results

The 43.2% presented an emphysematous phenotype, 44.7% were chronic bronchitic and the other 12.1% presented a phenotype showing mixed characteristics with asthma. There were no significant differences in the smoking level, in the gasometric values or time of disease evolution. Type 1 patients showed lower FEV₁ values in comparison with types 2 and 3, 46.6% (21.1), 55.2% (21.2) and 54.4% (21.8), respectively (p < 0.05), and greater levels of dyspnea (p < 0.05). No significant differences were observed in the percentage of patients who had at least one exacerbation in the last year (68.8%, 63.9%, 64.9%; p = 0.25), in the number of exacerbations (p = 0.56), in the number of visits to the ER (total and due to COPD), or in the number of hospital admittances. Type 2 patients showed a greater prevalence of cardiovascular comorbidities and of sleep apnea syndrome (4.9%, 23.6% and 12.5%, respectively, p < 0.001).

Conclusions

In COPD, emphysematous patients present worse pulmonary function and greater dyspnea, although there were no differences in the use of hospital health care resources. The greater comorbidity in Group 2 patients may require specific strategies in this subgroup of patients.

---

### Evaluation and differential diagnosis of marked, persistent eosinophilia [^e8cb46a1]. Immunology and Allergy Clinics of North America (2007). Low credibility.

Hypereosinophilic syndromes (HES) are a group of heterogeneous disorders many of which remain ill-defined. By definition, the HES must be distinguished from other disorders with persistently elevated eosinophilia with a defined cause. Although marked eosinophilia worldwide is most commonly caused by helminth (worm) infections, the diagnostic approach must include noninfectious (nonparasitic) causes of marked eosinophilia as well.

---

### Eosinophilia associated with immune deficiency [^00fd65cf]. The Journal of Allergy and Clinical Immunology: In Practice (2022). Medium credibility.

The differential diagnosis of eosinophilia is broad and includes infections, malignancies, and atopy as well as inborn errors of immunity (IEI). Certain types of IEIs are known to be associated with elevated numbers of eosinophils and frequently elevated serum IgE, whereas for others the degree and frequency of eosinophilia are less established. The molecular defects underlying IEI are heterogeneous and affect different pathways, which highlights the complex regulations of this cell population within the immune system. In this review, we list and discuss clinical manifestations and therapies of immune deficiency or immune dysregulation disorders associated with peripheral blood or tissue eosinophilia with or without raised IgE levels. We present illustrative case vignettes for the most common entities and propose a diagnostic algorithm aiming to help physicians systematically to evaluate patients with eosinophilia and suspicion of an underlying IEI.

---

### Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes [^705e892d]. Allergy (2023). Medium credibility.

11 CONCLUSIONS AND FUTURE PERSPECTIVES

Diagnosis and management of eosinophil‐associated disorders and related syndromes are an emerging challenge in the fields of clinical immunology, hematology, and pathology. With the recent availability of eosinophil‐depleting targeted drugs, it is now even more important to unify definitions and classifications for these conditions in an interdisciplinary effort. HE may develop in the context of various hematologic neoplasms and in certain reactive states. In all these patients, it is important to (i) document or exclude a related neoplastic or non‐neoplastic disease, and to (ii) document or exclude the presence of HE‐related organ damage (HES). Several immunological, serological, molecular, and cytogenetic markers are available to establish the nature of the underlying condition and, thus, help define the variant of HE and HES. In 2012, our consensus group proposed a comprehensive classification of eosinophil disorders together with diagnostic criteria. This proposal was based on a multidisciplinary approach involving the fields of allergy, immunology, hematology, pathology, and molecular medicine. Because of its multidisciplinary character and simple format, this concept has been widely accepted and is considered standard. However, recent developments in the field emerged and created a need to update and refine these concepts and diagnostic criteria. In the Year 2021 Working Conference on Eosinophil Disorders (Vienna, September 24–26, 2021), these developments were discussed and used to adjust diagnostic criteria, as well as definitions and classification of eosinophil disorders. As in 2011, these proposed criteria and definitions are based on a multidisciplinary approach and are in line with the previous ICOG‐EO consensus proposal and the 2016‐ and 2022‐updated classification of the WHO and ICC. We also define where the ICOG‐EO proposal complements or adds to the 2022‐updated WHO classification and ICC. Our updated definitions and criteria, along with our increasing knowledge about the etiology of HE should improve diagnosis, management, and prognosis of patients with eosinophil disorders in daily practice as well as in clinical trials.

---

### Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2025 report) [^2bc50d5f]. GOLD (2025). High credibility.

Clinical presentation — Patients with COPD typically report dyspnea, activity limitation and/or cough with or without sputum production and may experience acute respiratory events characterized by increased respiratory symptoms called exacerbations that require specific preventive and therapeutic measures, and they frequently harbor comorbid diseases that influence clinical condition and prognosis and require specific treatment, which can mimic and/or aggravate an acute exacerbation.

---

### Physicians ez use b-12 compliance [^964c3286]. FDA (2024). Medium credibility.

Uses

For first aid to decrease germs in

minor cuts
scrapes
burns

For preparation of the skin prior to injection

---

### Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults [^39fe5805]. United European Gastroenterology Journal (2017). Medium credibility.

Regarding screening and diagnosis for eosinophilic esophagitis, more specifically with respect to diagnostic criteria, EAACI/ESPGHAN/EUREOS/UEG 2017 guidelines recommend to set a 15 eosinophils/hpf (standard size of ~0.3 mm²) in esophageal mucosa, taken as the peak concentration in the specimens examined, as the threshold for eosinophil density for the diagnosis of EoE.

---

### Global Initiative for Chronic Obstructive Lung Disease 2023 report: GOLD executive summary [^e6f9657b]. American Journal of Respiratory and Critical Care Medicine (2023). Medium credibility.

New Definition of COPD

The definition of a disease should only include the characteristics that distinguish it from other diseases. Accordingly, GOLD 2023 proposes a new definition of COPD that, at variance with previous documents, focuses exclusively on these characteristics, separately from its epidemiology, causes, risk factors, and diagnostic criteria that are discussed on their own.

GOLD 2023 defines COPD as a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, expectoration, and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.

---

### Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report [^80ed4d92]. Chest (2020). High credibility.

Systematic review search results — study selection across the three questions found that of the citations initially identified, 3/1,175, 53/656, and 6/134 from the databases searched were eligible for inclusion in the three systematic reviews, respectively; flow diagrams with exclusion reasons are shown in Figures 1 through 3.